Imunon, Inc. IMNN
0.72 USD -0.05 (-6.48%)
At closeNov 11, 2026, 7:26 PM EST
0.75 +0.03 +4.29%
After hours · Nov 11, 7:26 PM ET
0.6819 Day range 0.7968
0.6819 52-week range 4.38
- YTD
- -81.10%
- 1 year
- -81.30%
News
globenewswire.com IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Curis (NASDAQ:CRIS) stock moved upwards by 83.5% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $1.7 million. SCWorx (NASDAQ:WORX) stock increased by…
globenewswire.com IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026 LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…
benzinga.com IMUNON Sells ThermoDox Rights To VoxelDox; IMUNON Receive Equity Ownership Stake In VoxelDox With Payments Of Up To $16.5M Contingent On Meeting Development Milestones And Royalties Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma TrialSale Reinforces IMUNON's…
globenewswire.com IMUNON Announces Strategic Sale of ThermoDox® Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial
globenewswire.com IMUNON to Participate in Upcoming Investor Conferences LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $34.9 million. Intelligent Bio Solutions…
globenewswire.com IMUNON Converts $1.2 Million of Debt-to-Equity Unique investment vehicle provides efficient access to equity capitalOutstanding debt of the original Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE,…
benzinga.com IMUNON Reports Overall Survival Results, Advances Phase 3 OVATION 3 Trial 2026 R&D Day presentation highlights include:Review of final Randomized Phase 2 overall survival resultsSupportive Preliminary MRD Study Data and translational findingsPathway to confirmatory readout…
globenewswire.com IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan 2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory…
seekingalpha.com Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript
benzinga.com IMUNON Says Independent Monitoring Committee Recommends Continuing IMNN-001 Phase 2 Study Without Modification Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to dateNo cytokine release syndrome, systemic…
globenewswire.com IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date
benzinga.com IMUNON Enters Into CRADA With National Cancer Institute To Advance DNA-Based IL‑12 Immunotherapy IMNN‑001 Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimensIMUNON retains ownership of its background intellectual property…
globenewswire.com IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre-market session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma…
benzinga.com IMUNON To Discuss OVATION 1 Clinical Study At Its Sept. 23 R&D Day IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced the agenda and speaker lineup for its upcoming R&D Day highlighting…
globenewswire.com IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J.
globenewswire.com IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones
seekingalpha.com Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript
benzinga.com Imunon Q2 EPS $(0.54) Beats $(0.93) Estimate Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.93) by 41.94 percent. This is a 74.88 percent increase over losses of $(2.15) per…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings…
globenewswire.com IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION 2…
benzinga.com EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study IMUNON posts rapid patient enrollment in its Phase 3 OVATION 3 trial for ovarian cancer, targeting completion by Q2 2029.
benzinga.com IMUNON To Present New Data On IMNN-001, DNA-Based Interleukin-12 Immunotherapy For Advanced Ovarian Cancer, At Inaugural AACR Conference On Drug Discovery And Development Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanismFirst-of-its-kind meeting spotlights…
globenewswire.com IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism
globenewswire.com IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial Lower rate of minimal residual disease (MRD)Higher ctDNA…
benzinga.com Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 minimal residual disease (MRD) translational trial.
benzinga.com Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients Imunon reports early Phase 2 data showing lower residual disease and higher ctDNA clearance with IMNN-001 in ovarian cancer.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.9 million. Imunon (NASDAQ:IMNN) shares…
benzinga.com Imunon Says Jeffrey Church To Retire As Interim CFO Effective July 1, 2026; Appoints Josh Blacher As Interim CFO Effective July 1, 2026 On June 29, 2026, Jeffrey Church informed Imunon, Inc. (the "Company") of his intent to retire from the position of interim Chief Financial Officer (a position he has held since January of 2026),…
benzinga.com IMUNON Receives Independent Data Monitoring Committee Recommended Continuation Of Pivotal Phase 3 OVATION 3 Clinical Trial Of IMNN-001 In Combination With Standard Of Care Neoadjuvant And Adjuvant Chemotherapy In Women With Newly Diagnosed Advanced Ovarian Cancer IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the independent Data Monitoring Committee (iDMC) has recommended…
globenewswire.com IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer…
globenewswire.com IMUNON to Present at the Life Sciences Investor Forum on June 25th LAWRENCEVILLE, N. J. , June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy…- benzinga.com IMUNON Enters Into Definitive Agreements For $10M In Preferred Stock And Secured Notes Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 millionUniquely structured, flexible financing supports IMUNON's Highly Anticipated Phase 3…
- benzinga.com Imunon Reports Q1 2026 Results: Full Earnings Call Transcript
- benzinga.com Imunon Q1 EPS $(0.84) Beats $(1.07) Estimate Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.07) by 21.5 percent. This is a 73.33 percent increase over losses of $(3.15) per…
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com Maxim Group Initiates Coverage On Imunon with Buy Rating, Announces Price Target of $10 Maxim Group analyst Jason McCarthy initiates coverage on Imunon (NASDAQ:IMNN) with a Buy rating and announces Price Target of $10.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Imunon Q4 EPS $(1.30) Misses $(1.13) Estimate Imunon (NASDAQ:IMNN) reported quarterly losses of $(1.30) per share which missed the analyst consensus estimate of $(1.13) by 15.04 percent. This is a 56.67 percent increase over losses of $(3.00)…
- benzinga.com Earnings Scheduled For March 31, 2026
- benzinga.com Watching Imunon; Zacks Small-Cap Research Gives Stock $33 Price Valuation https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03252026_IMNN_Bautz.pdf
- benzinga.com IMUNON Reports Improved Survival In OVATION 2 Trial, With IMNN-001 Extending Overall Survival Up To 24.2 Months The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysisPatients…
- benzinga.com IMUNON Eliminates Headcount Not Essential To Phase 3 Trial Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 StudyKhursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For November 13, 2025